Old Web
English
Sign In
Acemap
>
Paper
>
Capmatinib (INC280) in MET Delta EX14-Mutated Advanced NSCLC : Efficacy Data from the Phase 2 Geometry MONO-1 Study
Capmatinib (INC280) in MET Delta EX14-Mutated Advanced NSCLC : Efficacy Data from the Phase 2 Geometry MONO-1 Study
2019
R. S. Heist
Juergen Wolf
Takashi Seto
J. Y. Han
Noemi Reguart
Harry J.M. Groen
Daniel S. W. Tan
Toyoaki Hida
Maja J.A. de Jonge
Sergey Orlov
Egbert F. Smit
Pierre-Jean Souquet
Johan Vansteenkiste
Monica Giovannini
Sylvie Le Mouhaër
Anna Robeva
Maeve Waldron-Lynch
E. B. Garon
Keywords:
Capmatinib
Pathology
Medicine
Delta
Oncology
Internal medicine
Correction
Source
Cite
Save
0
References
0
Citations
NaN
KQI
[]
map